Optimal Treatments for NSCLC Patients Harboring Primary or Acquired <i>MET</i> AmplificationDantong Sun, Helei Hou, Hai Zhou et al.|Technology in Cancer Research & Treatment|2022Cited by 13
ARID1A deficiency associated with MMR deficiency and a high abundance of tumor-infiltrating lymphocytes predicts a good prognosis of endometrial carcinomaDantong Sun, Helei Hou, Han Zhao et al.|Translational Oncology|2023Cited by 11
Role of YES1 signaling in tumor therapy resistanceHai Zhou, Helei Hou, Dantong Sun et al.|Cancer Innovation|2023Cited by 10
Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective studyHai Zhou, Helei Hou, Dantong Sun et al.|Discover Oncology|2024Cited by 8
Next-generation sequencing identifies potential novel therapeutic targets in Chinese HGSOC patientsJunyan Tao, Helei Hou, Jingjuan Zhu et al.|Pathology - Research and Practice|2022Cited by 6